Literature DB >> 11303693

Lessons learned from statin trials.

J Auer1, R Berent, B Eber.   

Abstract

This article aims to review lessons learned about lipid lowering and statins in the past decade and to consider what developments the future may hold. Results from a series of landmark clinical trials confirm that statins significantly reduce cardiovascular morbidity and mortality in patients with and without previous coronary artery disease. The potential of this drug class has yet to be fully explored. Studies currently under way will answer many of the outstanding questions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303693      PMCID: PMC6654998          DOI: 10.1002/clc.4960240404

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  3 in total

1.  Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx.

Authors:  R Datar; W H Kaesemeyer; S Chandra; D J Fulton; R W Caldwell
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Pharmacogenetics of lipid diseases.

Authors:  Jose M Ordovas
Journal:  Hum Genomics       Date:  2004-01       Impact factor: 4.639

3.  Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study.

Authors:  Alireza Sadighi; Javid Safa; Amir-Mansour Vatankhah; Sona Ghorashi; Aida Aharilahagh; Sina Davari-Farid; Ourmaan Nezami-Nargabad; Mohammad Naghavi-Behzad; Reza Piri; Parinaz Pishahang; Savalan Babapoor-Farrokhran; Sanam Fakour; Nastaran Ghodratnezhad-Azar
Journal:  Niger Med J       Date:  2016 Sep-Oct
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.